Company intelligence / Profile preview
Agomab Therapeutics
Antwerp, Antwerp Province, Belgiumagomab.com ↗
- Ownership
- Public · AGMB
- Employees
- ~75
- Development stage
- Phase 2
01
Overview
Agomab’s lead asset, AGMB-129, a GI-restricted oral small molecule ALK5 inhibitor for fibrostenosing Crohn’s disease, has shown positive topline interim results in a Phase 2a trial—meeting all primary and secondary endpoints after twelve weeks of treatment. The company also has a lung-restricted ALK5 inhibitor in early clinical development for IPF and two MET agonist antibodies advancing toward the clinic. An open-label extension study for AGMB-129 is ongoing[1][8].
- Therapeutic areas
- OtherGastroenterologyPulmonology
- Modalities
- Small molecules (e.g., ALK5 inhibitors)Monoclonal antibodies (agonistic mAbs targeting MET)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations with leading academic institutionsinvestors include major pharma/biotech funds such as Pfizer Ventures and Boehringer Ingelheim Venture Fund[7][4][6]
04
Financials
- Market cap
- $736.7M
- Total revenue
- $0
- Enterprise value
- $485.9M
Beyond the preview
Go deeper on Agomab Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agomab Therapeutics.